These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 15765889)

  • 1. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis.
    van Oostrom AJ; van Wijk J; Cabezas MC
    Drugs; 2004; 64 Suppl 2():19-41. PubMed ID: 15765889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postprandial inflammation and endothelial dysfuction.
    Alipour A; Elte JW; van Zaanen HC; Rietveld AP; Cabezas MC
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):466-9. PubMed ID: 17511629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current, new and future treatments in dyslipidaemia and atherosclerosis.
    Chong PH; Bachenheimer BS
    Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures.
    De Lorenzo F; Collot-Teixeira S; Boffito M; Feher M; Gazzard B; McGregor JL
    Curr Med Chem; 2008; 15(28):2991-9. PubMed ID: 19075647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focusing on inflammation in the treatment of atherosclerosis.
    Call JT; Deliargyris EN; Newby LK
    Cardiol Rev; 2004; 12(4):194-200. PubMed ID: 15191631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effects of statins in atherosclerosis: role on endothelial function, inflammation and immunomodulation.
    Arnaud C; Mach F
    Arch Mal Coeur Vaiss; 2005 Jun; 98(6):661-6. PubMed ID: 16007821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins meditate anti-atherosclerotic action in smooth muscle cells by peroxisome proliferator-activated receptor-γ activation.
    Fukuda K; Matsumura T; Senokuchi T; Ishii N; Kinoshita H; Yamada S; Murakami S; Nakao S; Motoshima H; Kondo T; Kukidome D; Kawasaki S; Kawada T; Nishikawa T; Araki E
    Biochem Biophys Res Commun; 2015 Jan; 457(1):23-30. PubMed ID: 25529449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease].
    Galle J
    Herz; 2004 Feb; 29(1):4-11. PubMed ID: 14968336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid lowering therapy in atherosclerosis.
    Aikawa M; Libby P
    Semin Vasc Med; 2004 Nov; 4(4):357-66. PubMed ID: 15861316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Free fatty acids: mediators of insulin resistance and atherosclerosis].
    Castro Cabezas M; Erkelens DW; van Dijk H
    Ned Tijdschr Geneeskd; 2002 Jan; 146(3):103-9. PubMed ID: 11826668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein.
    Wang HR; Li JJ; Huang CX; Jiang H
    Clin Chim Acta; 2005 Mar; 353(1-2):53-60. PubMed ID: 15698590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits.
    Mitani H; Egashira K; Ohashi N; Yoshikawa M; Niwa S; Nonomura K; Nakashima A; Kimura M
    Pharmacology; 2003 Jul; 68(3):121-30. PubMed ID: 12784083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel aspects of postprandial lipemia in relation to atherosclerosis.
    Alipour A; Elte JW; van Zaanen HC; Rietveld AP; Castro Cabezas M
    Atheroscler Suppl; 2008 Sep; 9(2):39-44. PubMed ID: 18595782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages.
    Yano M; Matsumura T; Senokuchi T; Ishii N; Murata Y; Taketa K; Motoshima H; Taguchi T; Sonoda K; Kukidome D; Takuwa Y; Kawada T; Brownlee M; Nishikawa T; Araki E
    Circ Res; 2007 May; 100(10):1442-51. PubMed ID: 17463321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [NO and atherosclerosis].
    Ohtani K; Egashira K
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():544-7. PubMed ID: 15506446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.